论文部分内容阅读
目的观察氟维司群治疗一线内分泌治疗失败后晚期乳腺癌的疗效。方法选取大连市妇女儿童医疗中心2014年1月至2015年1月收治的一线内分泌治疗失败后晚期乳腺癌患者40例,随机分为对照组及观察组,各20例。两组患者均给予氟维司群治疗,对照组剂量为250 mg,观察组剂量为500 mg。观察患者临床疗效及不良反应发生情况。结果治疗后,观察组治疗后客观缓解率及获益率分别为30.0%、90.0%,均略高于对照组的25.0%、75.0%,但差异无统计学意义(P>0.05);治疗后,两组患者均出现轻微不良反应,且随着治疗时间延长自行消失。结论对一线治疗失败后晚期乳腺癌患者给予氟维司群治疗,临床疗效显著,患者治疗期间不良反应轻微,且随着治疗时间延长自行消失,药物安全性好,值得临床推广应用。
Objective To observe the efficacy of fulvestrant in the treatment of advanced breast cancer after failed first-line endocrine therapy. Methods Forty patients with advanced breast cancer who failed in first-line endocrine therapy admitted to Dalian Women and Children’s Medical Center from January 2014 to January 2015 were randomly divided into control group and observation group, with 20 cases in each group. Fulvestrant was given to both groups, with a control group of 250 mg and a study group of 500 mg. Observed the clinical efficacy and adverse reactions occurred. Results After treatment, the objective response rate and benefit rate in the observation group were 30.0% and 90.0%, respectively, which were slightly higher than those in the control group (25.0% and 75.0%, respectively), but the difference was not statistically significant (P> 0.05) , Two groups of patients showed mild adverse reactions, and disappear on their own with the extension of treatment time. Conclusions The treatment of fulvestrant in patients with advanced breast cancer after failed first-line therapy is clinically effective. The adverse reactions during treatment are slight and disappear with the prolongation of treatment time. The drug is safe and worthy of clinical application.